Sox2 amplification was recently reported as a common event in squamous cell carcinomas (SCCs) occurring at different anatomic sites including the lung. The objective of the study was to determine morphologic and clinicopathologic characteristics of lung SCCs with respect to
Early studies of molecular carcinogenesis of squamous cell carcinomas (SCCs) showed that chromosome 3 aberrations are very common and are responsible for the development and progression of this carcinoma. 1-3 Studies using highresolution arrays identified the sex-determining region Y-box 2 (Sox2) gene at 3q26.33 as a lineage-survival oncogene in SCC. Sox2 is a 317-amino acid transcription factor containing an HMG domain that is a critical transcription regulator of normal stem cell function in embryonic and neural stem cells. [4] [5] [6] Sox2 is essential for early mammalian development and for the maintenance of both pluripotent embryonic stem cells and stem cells in multiple adult tissues. [7] [8] [9] Two independent groups identified Sox2 as a major oncogene in lung and esophageal SCC. 10, 11 Sox2 protein expression and/or gene amplifications were also documented in SCCs at various anatomic sites. 12 Sox2 protein expression and gene amplification are found in a large number of SCCs, and only rarely in adenocarcinomas (ADCs) and neuroendocrine tumors. [13] [14] [15] [16] [17] Sox2 expression and amplification were also found in preinvasive squamous cell lesions such as dysplasia and carcinoma in situ, and were absent in the pulmonary ADC precursor atypical adenomatous hyperplasia. [17] [18] [19] [20] Both expression and amplification of Sox2 were shown to be associated with better outcome in SCC. 16 The prognostic significance of Sox2 expression in lung ADC is controversial and only 1 study demonstrated its negative prognostic significance in stage I ADC. 21 There is a suggestion that Sox2 expression and amplification are associated with low-grade tumors; however, none of the published studies provided detailed histologic descriptions of SCC. 12, 16 In the current study, we performed a comprehensive histologic evaluation of pulmonary SCCs and compared morphology and outcome between the tumors with and without Sox2 expression and amplification.
Materials and Methods
A total of 147 primary non-small cell lung cancers (70 SCC and 77 ADC) in patients who underwent surgical resection at the University of Pittsburgh Medical Center (Pittsburgh, PA) were selected for the study. Patients who received prior radiation, neoadjuvant, or adjuvant cytotoxic chemotherapy were excluded from the analysis. Clinical and pathologic information including age, gender, tumor stage, surgical procedure, smoking history, pleural invasion, angiolymphatic invasion, tumor-infiltrating lymphocytes, and outcome were obtained from a review of patients' electronic medical records ❚Table 1❚. Of these, 39 were central and 31 peripheral SCCs. Central SCCs were limited to a lobar bronchus, and peripheral SCCs arose in the periphery of lung parenchyma distal to the fifth bronchial bifurcation. The SCC group included 1 never smoker, 29 former smokers, and 25 current smokers. The ADC group included 13 never smokers, 20 former smokers, and 33 current smokers. Smoking history was uncertain in 26 patients. Six patients were unavailable for follow-up.
All H&E histologic sections of the tumors were reviewed by 2 pathologists (S.D. and L.B.). Histologic type was determined according to 2004 World Health Organization classification criteria. 22 SCCs were assessed for necrosis, presence of intercellular bridges, keratin pearls, nuclear atypia (mild, moderate, severe), stroma (fibroelastotic, fibromyxoid, and desmoplastic), and basaloid and clear cell differentiation. Mild nuclear atypia was defined as relatively uniform nuclei with indistinct nucleoli; moderate atypia as relatively uniform nuclei with distinct nucleoli; and severe atypia as enlarged nuclei of varied sizes including bizarre and giant forms, with or without nucleoli at a magnification of ×40. The highest degree of atypia was recorded in morphologically heterogeneous tumors. Basaloid features were defined by a proliferation of relatively small cells with a typical high mitotic rate, forming a lobular pattern with peripheral palisading and comedo-type necrosis. The presence of basaloid features was recorded in 5% increments. Clear cell changes were defined as the presence of tumor cells with clear cytoplasm and were recorded as present or absent. The presence of visceral pleural invasion, angiolymphatic invasion and tumor infiltrating lymphocytes (low and high) was also assessed.
Tissue microarrays of ADC used for fluorescence in situ hybridization (FISH) and immunohistochemical (IHC) studies were constructed from a representative block from formalin-fixed, paraffin-embedded archival tissue specimens, as previously reported. 23 FISH and IHC analysis of SCC were performed on whole tissue sections.
Immunohistochemistry
Sox2 rabbit monoclonal antibody (1:100; clone D6D9; Cell Signaling Technology, Danvers, MA) was used. Sox2 nuclear staining was interpreted based on 2 criteria as previously described. 21 One approach was to interpret the results of Sox2 IHC studies as negative or positive using a 5% cutoff. The second approach was semiquantitative and defined as follows: 0, no staining; 1+, less than 5%; 2+, 5% to 25%; 3+, 26% to 50%; and 4+, greater than 50% of tumor cells. Proliferation index was assessed using Ki-67 (1:100; clone MIB1; DAKO, Carpinteria, CA).
FISH
FISH analysis of Sox2 amplification was performed using a spectrum green-labeled probe RP11-286G5 (CHORI, Oakland, CA), spectrum orange-labeled probe RP11-43F17 (CHORI), and paraffin pretreatment reagent kit (Vysis, Downers Grove, IL). In brief, paraffin sections were deparaffinized, dehydrated in ethanol, and air-dried. Sections were digested with protease K (0.5 mg/mL) at 37°C for 28 minutes. The slides were denatured at 75°C for 5 minutes and dehydrated in ethanol. The probes were denatured for 5 
Statistical Analysis
Sox2 expression and amplification were compared using Fisher exact test, Spearman or Kendall t-β correlation, Wilcoxon two-sample test, or Kruskal-Wallis test. Overall survival (OS) distributions were estimated with the KaplanMeier method, with the log-rank test being used to assess the difference among groups. The relationship of OS to Sox2 was further assessed with the Cox proportional hazards regression.
Statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). A significance level was set at .05 and all P values reported were 2-sided. Although patients with Sox2 FISH-positive tumors showed a trend toward better survival, this difference was not statistically significant (P = .43, with the log-rank test on Kaplan-Meier estimates) ❚Figure 1A❚. In contrast, Sox2 IHC-positive SCC showed a significantly better OS than the negative group (P = .0489). The median survival time for patients with Sox2 IHC-positive SCC was 66 months (95% CI, 49-92). The median survival time for patients with Sox2 IHC-negative SCC was 14 months (95% CI, 8-72) ❚Figure 1B❚. However, Cox proportional hazards regression analysis failed to demonstrate Sox2 protein expression to be an independent prognostic factor in SCC. Survival analysis in the ADC group was limited because only 6 tumors showed Sox2 FISH amplification. In the ADC group, no significant association was detected between Sox2 FISH ratio and survival time (P = .68 with the log-rank test on Kaplan-Meier estimates). The median survival time for patients with ADC negative for amplification was 61 months (95% CI, 45). No difference in survival time was found with respect to Sox2 protein expression (P = .71). 
Results

Sox2
Discussion
This study demonstrates a prognostic significance of Sox2 expression in SCC and identifies morphologic features of SCC associated with Sox2 protein expression. Prior studies that looked into Sox2 expression in non-small cell lung cancer either did not explore morphology in great detail or did not provide definitions of grade criteria. 16 Assessment of the tumor grade is usually rather subjective and qualitative. Therefore, instead of separating the tumors into well, moderately, or poorly differentiated categories, we used a quantitative and semiquantitative approach to determine the presence of keratinization, intercellular bridges, tumor necrosis, and nuclear atypia. To our knowledge, our study is the first to show that SCCs expressing high levels of Sox2 exhibit a higher grade of nuclear atypia, usually manifesting as larger nuclei, sometimes with bizarre forms with or without nucleoli. This association was not seen in Sox2-amplified tumors, suggesting that mechanisms other than amplification may be responsible for Sox2 protein expression. Hussenet et al 11 reported that BEAS-B2-SOX2 cells injected into immunocompromised mice gave rise to slowly growing, poorly differentiated SCC of the basaloid phenotype. We confirmed this observation in our study using human tumor tissue material. We showed that a higher percentage of basaloid features is associated with higher Sox2 protein expression. Similar to nuclear atypia, the presence of basaloid features was not associated with Sox2 amplification. The reason for this difference is unclear. It has been suggested that 3q26.3 locus may be a new multioncogenic locus. 24 It is uncertain if other genes at that locus are codrivers that modulate tumor phenotype and have an effect on Sox2 protein expression independent of gene amplification. It is possible that Sox2 is regulated at multiple levels including DNA, RNA, and protein, all of which should be explored separately to elucidate regulation of Sox2 protein expression.
A possible difference in clinical behavior between central and peripheral SCC has been suggested. [25] [26] [27] A subset of peripheral SCCs may also show a phenomenon of air space filling which demonstrates cohesive aggregates of squamous carcinoma filling air spaces with intact alveolar septa. Yousem 27 showed that the presence of this feature would lead to adjustment of the tumor size with a subsequent downstaging in about 26% of stage I SCCs; however, a limited number of cases precluded reliable survival and outcome analyses. In a study of 81 peripheral SCCs, Watanabe et al 26 observed no relapse in patients with a ratio of alveolar space filling area to tumor area of 70% or more and a maximum diameter of invasive area measuring 10 mm or less in size. We are not aware of molecular studies comparing these 2 subsets of SCC. Our study failed to demonstrate any differences in Sox2 protein expression and gene amplification in these 2 groups of SCC, including the presence or absence of air space filling. It is possible that Sox2 is a marker of squamous differentiation and its overexpression or gene amplification is independent of tumor location.
Similar to prior studies, our results confirmed that Sox2 protein overexpression predicts a good prognosis in SCC, but is not an independent prognostic factor. Similar to the Wilbertz et al 16 study, Sox2 amplification showed a trend toward better survival, but that observation did not reach statistical significance. Wilbertz et al 16 reported that a trend toward better survival was seen only in a group with a high amplification. We did not find any difference between low and high levels of amplification. The underlying reason for this difference is uncertain. It would be interesting to explore a potential prognostic significance of different interpretation criteria on a larger group of cases. Sox2 is not therapeutically targetable at the present time and the development of targeted therapies in SCC is much slower than in ADC. Hopefully, Sox2 will eventually become a target for drug therapy, and identification of Sox2 protein expression and/or gene amplification may help to identify patients who might benefit from this particular targeted therapy. Furthermore, a prognostic significance of Sox2 IHC and FISH in patients treated with platinum-based therapies is unexplored. It would be interesting to learn if Sox2 status is a potential modifier of response.
The prognostic role of Sox2 expression in lung ADC is controversial. Sholl et al 21 reported that Sox2 expression is an independent predictor of poor outcome in stage I lung ADC. Wilbertz et al 16 failed to demonstrate this association in their study cohort. Furthermore, no association between Sox2 gene copy number and outcome in lung ADC was found. Sox2 protein overexpression and gene amplification in our group of ADCs was infrequent, which precluded any reliable survival analysis. Our observation is consistent with that of Yuan et al 17 who demonstrated absent or very infrequent expression of Sox2 in atypical adenomatous hyperplasia and invasive lung adenocarcinoma.
In summary, our study confirmed observations that Sox2 expression and amplification are strongly associated with SCC morphology and better outcome. In contrast, both events are very infrequent in ADC and are of uncertain prognostic significance. It appears that Sox2 overexpression is frequent
